$16.80
-0.01-0.06%
Last update: 9:28 AM
15 minutes delayed
Comments
Loading...
Teva Pharmaceutical Indus
TEVANYSE
Unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
Teva Pharmaceutical Indus (NYSE:TEVA) Stock, Analyst Ratings, Price Targets, Forecasts
Teva Pharmaceutical Industries Ltd has a consensus price target of $16.18 based on the ratings of 14 analysts. The high is $24 issued by UBS on July 10, 2024. The low is $10 issued by Morgan Stanley on May 25, 2023. The 3 most-recent analyst ratings were released by UBS, Jefferies, and Barclays on July 10, 2024, June 27, 2024, and June 5, 2024, respectively. With an average price target of $22.67 between UBS, Jefferies, and Barclays, there's an implied 34.92% upside for Teva Pharmaceutical Industries Ltd from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
UBS
Jefferies
Barclays
B of A Securities
Piper Sandler
1calculated from analyst ratings
Analyst Ratings for Teva Pharmaceutical Indus
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 07/10/2024 | Buy Now | 42.86% | UBS | Ashwani Verma | $22 → $24 | Maintains | Buy | Get Alert |
| 06/27/2024 | Buy Now | 36.9% | Jefferies | Glen Santangelo | $19 → $23 | Maintains | Buy | Get Alert |
| 06/05/2024 | Buy Now | 25% | Barclays | Balaji Prasad | $20 → $21 | Maintains | Overweight | Get Alert |
| 05/30/2024 | Buy Now | 25% | B of A Securities | Jason Gerberry | $18 → $21 | Maintains | Buy | Get Alert |
| 05/13/2024 | Buy Now | 19.05% | Piper Sandler | David Amsellem | $19 → $20 | Reiterates | Overweight → Overweight | Get Alert |
| 05/09/2024 | Buy Now | 19.05% | Barclays | Balaji Prasad | $17 → $20 | Maintains | Overweight | Get Alert |
| 03/08/2024 | Buy Now | -16.67% | JP Morgan | Chris Schott | → $14 | Upgrade | Underweight → Neutral | Get Alert |
| 02/12/2024 | Buy Now | 13.1% | Piper Sandler | David Amsellem | $12 → $19 | Upgrade | Neutral → Overweight | Get Alert |
| 02/05/2024 | Buy Now | -34.52% | Goldman Sachs | Nathan Rich | $10 → $11 | Maintains | Neutral | Get Alert |
| 02/05/2024 | Buy Now | 1.19% | Barclays | Balaji Prasad | $15 → $17 | Maintains | Overweight | Get Alert |
| 01/29/2024 | Buy Now | -10.71% | Barclays | Balaji Prasad | $14 → $15 | Maintains | Overweight | Get Alert |
| 01/23/2024 | Buy Now | -16.67% | Jefferies | Glen Santangelo | $10 → $14 | Upgrade | Hold → Buy | Get Alert |
| 01/03/2024 | Buy Now | -28.57% | Piper Sandler | David Amsellem | $8 → $12 | Upgrade | Underweight → Neutral | Get Alert |
| 12/18/2023 | Buy Now | -22.62% | HSBC | Rajesh Kumar | → $13 | Initiates | → Buy | Get Alert |
| 11/27/2023 | Buy Now | -22.62% | UBS | Ashwani Verma | $11 → $13 | Upgrade | Neutral → Buy | Get Alert |
| 09/20/2023 | Buy Now | -34.52% | UBS | Ashwani Verma | $8 → $11 | Maintains | Neutral | Get Alert |
| 09/08/2023 | Buy Now | -22.62% | B of A Securities | Jason Gerberry | $12 → $13 | Maintains | Buy | Get Alert |
| 07/06/2023 | Buy Now | -52.38% | UBS | Ashwani Verma | $7 → $8 | Upgrade | Sell → Neutral | Get Alert |
| 05/25/2023 | Buy Now | -40.48% | Morgan Stanley | Thibault Boutherin | → $10 | Initiates | → Equal-Weight | Get Alert |
| 05/18/2023 | Buy Now | — | Evercore ISI Group | Umer Raffat | — | Upgrade | In-Line → Outperform | Get Alert |
| 05/11/2023 | Buy Now | -34.52% | B of A Securities | Jason Gerberry | $13 → $11 | Maintains | Buy | Get Alert |
| 02/09/2023 | Buy Now | -16.67% | Barclays | Balaji Prasad | $13 → $14 | Maintains | Overweight | Get Alert |
| 01/19/2023 | Buy Now | -28.57% | Jefferies | Glen Santangelo | $10 → $12 | Downgrade | Buy → Hold | Get Alert |
| 11/23/2022 | Buy Now | -58.33% | Piper Sandler | David Amsellem | $8 → $7 | Maintains | Underweight | Get Alert |
| 11/14/2022 | Buy Now | -40.48% | JP Morgan | Chris Schott | $11 → $10 | Downgrade | Neutral → Underweight | Get Alert |
| 11/07/2022 | Buy Now | -40.48% | BMO Capital | Gary Nachman | $11 → $10 | Maintains | Market Perform | Get Alert |
| 10/21/2022 | Buy Now | -40.48% | Jefferies | Glen Santangelo | → $10 | Assumes | → Buy | Get Alert |
| 08/05/2022 | Buy Now | -22.62% | B of A Securities | Jason Gerberry | $10 → $13 | Upgrade | Neutral → Buy | Get Alert |
| 08/02/2022 | Buy Now | -40.48% | Goldman Sachs | Nathan Rich | $9 → $10 | Maintains | Neutral | Get Alert |
| 06/14/2022 | Buy Now | -40.48% | UBS | Ashwani Verma | → $10 | Initiates | → Neutral | Get Alert |
| 05/17/2022 | Buy Now | -46.43% | B of A Securities | Jason Gerberry | → $9 | Upgrade | Underperform → Neutral | Get Alert |
| 05/12/2022 | Buy Now | -46.43% | Goldman Sachs | Nathan Rich | $10 → $9 | Maintains | Neutral | Get Alert |
| 05/04/2022 | Buy Now | -58.33% | Piper Sandler | David Amsellem | $11 → $7 | Downgrade | Neutral → Underweight | Get Alert |
| 04/05/2022 | Buy Now | -22.62% | Barclays | Balaji Prasad | $11 → $13 | Upgrade | Equal-Weight → Overweight | Get Alert |
| 02/18/2022 | Buy Now | -34.52% | Barclays | Balaji Prasad | $13 → $11 | Maintains | Equal-Weight | Get Alert |
| 01/27/2022 | Buy Now | — | Argus Research | Jasper Hellweg | — | Downgrade | Buy → Hold | Get Alert |
| 10/28/2021 | Buy Now | — | Raymond James | Elliot Wilbur | — | Downgrade | Outperform → Market Perform | Get Alert |
| 07/29/2021 | Buy Now | -16.67% | Raymond James | Elliot Wilbur | — | Maintains | Outperform | Get Alert |
| 07/29/2021 | Buy Now | -34.52% | Wells Fargo | Jacob Hughes | — | Maintains | Equal-Weight | Get Alert |
FAQ
What is the target price for Teva Pharmaceutical Indus (TEVA) stock?
The latest price target for Teva Pharmaceutical Indus (NYSE:TEVA) was reported by UBS on July 10, 2024. The analyst firm set a price target for $24.00 expecting TEVA to rise to within 12 months (a possible 42.86% upside). 17 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Teva Pharmaceutical Indus (TEVA)?
The latest analyst rating for Teva Pharmaceutical Indus (NYSE:TEVA) was provided by UBS, and Teva Pharmaceutical Indus maintained their buy rating.
When was the last upgrade for Teva Pharmaceutical Indus (TEVA)?
The last upgrade for Teva Pharmaceutical Industries Ltd happened on March 8, 2024 when JP Morgan raised their price target to $14. JP Morgan previously had an underweight for Teva Pharmaceutical Industries Ltd.
When was the last downgrade for Teva Pharmaceutical Indus (TEVA)?
The last downgrade for Teva Pharmaceutical Industries Ltd happened on January 19, 2023 when Jefferies changed their price target from $10 to $12 for Teva Pharmaceutical Industries Ltd.
When is the next analyst rating going to be posted or updated for Teva Pharmaceutical Indus (TEVA)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Teva Pharmaceutical Indus, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Teva Pharmaceutical Indus was filed on July 10, 2024 so you should expect the next rating to be made available sometime around July 10, 2025.
Is the Analyst Rating Teva Pharmaceutical Indus (TEVA) correct?
While ratings are subjective and will change, the latest Teva Pharmaceutical Indus (TEVA) rating was a maintained with a price target of $22.00 to $24.00. The current price Teva Pharmaceutical Indus (TEVA) is trading at is $16.80, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.